People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aeovian Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $125.0M | $297.8M | 2023 |
Davis C. Ryman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Davis C. Ryman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Powell | 1 | 14 |
| Jens Eckstein | 1 | 8 |
| Richard Gaster | 1 | 7 |
| Ben Zadik | 1 | 6 |
| David Lowe | 1 | 5 |
| James Peyer | 1 | 3 |
| Ian Massey | 1 | 2 |
| Matthew J. Plunkett | 1 | 2 |
| Davis J. Ryman | 1 | 1 |
| William J. Greene | 1 | 1 |
| Micah J. Zajic | 1 | 1 |
| Lars J. Ekman | 1 | 1 |
| Justin J. Gover | 1 | 1 |
| Allison J. Hulme | 1 | 1 |
| Richard J. Gaster | 1 | 1 |
| Nils C. Regge | 1 | 1 |
| William C. Greene | 1 | 1 |
| John F. Kincaid | 1 | 1 |
| Richard C. Gaster | 1 | 1 |
| Lars C. Ekm | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.